Liposomes for Targeting Cancer: One Step Closer to the Holy Grail of Cancer Therapeutics?Neha Vaghasia1 and Noah Federman1,2*
- *Corresponding Author:
- Dr. Noah Federman, M.D.
Department of Pediatrics, Hematology/Oncology
Mattel Children’s Hospital at UCLA
UCLA’s David Geffen School of Medicine, Los Angeles, CA,USA
E-mail : [email protected]
Received date: September 02, 2011; Accepted date: November 08, 2011; Published date: November 10, 2011
Citation: Vaghasia N, Federman N (2011) Liposomes for Targeting Cancer: One Step Closer to the Holy Grail of Cancer Therapeutics? J Nanomedic Biotherapeu Discover 1:105e. doi:10.4172/2155-983X.1000105e
Copyright: © 2011 Vaghasia N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The use of plant-based medicines and various minerals to treat diseases is believed to date back to prehistoric medicine. Ancient texts from the Ramayana and The Papyrus Ebers make references to malignant diseases and their treatments . However, it was not until the early twentieth century that the first modern drugs to treat cancer came about. Mustard gas, initially intended for use as a chemical warfare agent during World War I, was found to be a potent suppressor of hematopoiesis . Goodman and Gilman later studied the Nitrogen Mustards as an effective treatment for cancers. Their findings were later applied successfully, however short lived, in the treatment of lymphoma . Thus, the field of chemotherapy was born! Since then, numerous chemotherapeutic agents have been designed and discovered for the treatment of various oncologic malignancies. Unable to truly differentiate cancerous from normal cells, these systemic chemotherapeutic agents often have significant bystander effects resulting in dose limiting toxicities, and not infrequently to permanent end organ damage. The future of cancer therapy has thus rested on the development of targeted therapies that would both increase the cytotoxicity to cancer cells while limiting the deleterious effects on normal cells.